MONOPAR THERAPEUTICS INC (MNPR)
US61023L1089 - Common Stock
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments
In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare DiseaseTwo Novel Radiopharma Clinical Trials now Active...
Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage...
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage...
Stay updated with the stocks that are on the move in today's after-hours session.
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock
WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage...
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
WILMETTE, Ill., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing...
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024
WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on...
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers
WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on...
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule
WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers
WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr
WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
MNPR stock results show that Monopar Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Monopar Therapeutics (NASDAQ:MNPR) just reported results for the second quarter...
Monopar Therapeutics Announces 1-for-5 Reverse Stock Split
WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing...